RGCC Group

RGCC Group is a Swiss-based biotechnology company specializing in personalized oncology and medical genetics. The company is a global leader in the isolation and analysis of circulating tumor cells (CTCs) and cancer stem cells (CSCs) using proprietary liquid biopsy technologies. Their comprehensive diagnostic portfolio, including the Onconomics and OncoTrace series, provides clinicians with data on tumor sensitivity to chemotherapy, targeted therapies, and natural substances. Beyond diagnostics, RGCC develops personalized therapeutic interventions such as Supportive Oligonucleotide Technique (SOT) and autologous immunotherapies. The group operates a network of specialized laboratories and collaborates with healthcare providers worldwide to integrate precision medicine into cancer management. Their research focus extends to the molecular characterization of tumors to identify early-stage disease and monitor treatment efficacy.